Skip to main content

The Signal: Nanoscope Therapeutics

Published

Apr 13, 2026

At Nanoscope Therapeutics, the mission is clear: restore vision and improve quality of life for individuals facing retinal degeneration. With MCO‑010 - the first optogenetic investigational therapy to show potential vision restoration in clinical trials - the future is coming into focus. Hear from Sulagna Bhattacharya, CEO and Co-Founder, and Samarendra Mohanty, President, Chief Scientific Officer & Co-Founder on where it's headed.

No transcript available

My Quotes
My European Quotes
Watchlist

View as Table

now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ETFs and more asset classes.

/

View as Table

now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Shares, Indexes, ETP and more asset classes.

/

Edit Watchlist

Your Watchlist is empty.

Create your Watchlist to save your favorite quotes on Nasdaq.com. Log in or create a free account to get started.

/